Navigating the market for laboratory-grade growth hormone-releasing hormone (GHRH) analogs requires a thorough understanding of analytical verification, chemical synthesis standards, and structural modifications. Evaluating the true CJC 1295 price involves assessing lot-specific purity, mass spectrometry validation, and endotoxin safety thresholds across qualified suppliers.
Navigating the market for laboratory-grade growth hormone-releasing hormone (GHRH) analogs requires a thorough understanding of analytical verification, chemical synthesis standards, and structural modifications. Evaluating the true CJC 1295 price involves assessing lot-specific purity, mass spectrometry validation, and endotoxin safety thresholds across qualified suppliers.
High-purity, research-grade CJC-1295 typically ranges from $30 to $80+ per vial depending on total peptide mass (e.g., 2 mg vs. 5 mg), structural variations such as the presence or absence of the Drug Affinity Complex (DAC), and analytical validation rigor. Vendor pricing directly reflects manufacturing compliance, including ISO 17025 third-party testing, high-performance liquid chromatography purity verification exceeding 99%, mass spectrometry identity confirmation, and low endotoxin thresholds.
When evaluating the raw CJC 1295 price from specialized peptide manufacturers, principal investigators must look beyond the initial purchase cost per milligram. Low nominal pricing often indicates unverified batch processing, lack of lot-specific Certificate of Analysis (COA) documents, or elevated residual trifluoroacetic acid (TFA) and endotoxin content. Institutional buyers acquiring compounds through wholesale lab accounts generally realize volume efficiency without sacrificing stringent analytical standards.
CJC-1295 is a synthetic 29-amino-acid peptide analog of naturally occurring Growth Hormone-Releasing Hormone (GHRH). It interacts directly with the GHRH receptor in pituitary somatotrophs to stimulate pulsatile growth hormone (GH) transcription and release. In preclinical models, sustained activation of the GHRH receptor leads to elevated levels of downstream insulin-like growth factor 1 (IGF-1), which is frequently measured in laboratory studies investigating cellular proliferation, tissue repair, and metabolic kinetics.
The primary chemical distinction within this class centers on the inclusion of the Drug Affinity Complex (DAC). Modified GHRH (1-29), commonly referenced as CJC-1295 No DAC, exhibits a rapid systemic elimination half-life of approximately 30 minutes in animal models. Conversely, CJC-1295 DAC contains a reactive lysine residue coupled to a maleimide linker that covalently binds to circulating serum albumin upon administration in vivo. This modification extends the biological half-life to several days in preclinical rodent models, drastically altering the pharmacokinetic profile and downstream receptor occupancy during long-term tissue repair investigations.
To properly contextualize the research expenditure of GHRH analogs, researchers frequently compare the cost-to-potency ratio of CJC-1295 against other secretagogues within the same mechanistic category. For example, short-acting GHRH derivatives like Sermorelin feature a lower per-vial cost but exhibit significantly faster enzymatic degradation in vitro and in vivo. Meanwhile, combining GHRH analogs with selective growth hormone secretagogue receptor (GHSR) agonists like Ipamorelin or GHRP-6 is a common strategy in dual-receptor signaling research.
When evaluating market value across the secretagogue spectrum, CJC-1295 with DAC commands a higher manufacturing premium due to the added chemical complexity of the maleimide-based coupling moiety. Researchers comparing unit costs must factor in the total peptide stability and intended assay duration. Detailed cross-comparisons of receptor kinetics and peptide longevity are available in our comprehensive growth hormone secretagogues guide.
The single largest contributor to legitimate CJC 1295 price variance across vendors is the extent of analytical quality control applied to each synthesized lot. Solid-phase peptide synthesis (SPPS) yields crude peptide mixtures containing truncated sequences, deletion peptides, and chemical counter-ions. Transforming crude product into research-grade peptide requires iterative purification via preparative Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC).
A reliable supplier provides batch-specific testing documents verified by an independent ISO 17025 accredited laboratory. Each Certificate of Analysis (COA) must detail two primary metrics: RP-HPLC chromatograms showing relative purity (target >= 99.0%) and Electrospray Ionization Mass Spectrometry (ESI-MS) confirming exact molecular mass. Cheaper market alternatives frequently omit lot-matched testing, relying instead on generic static reports that do not guarantee the chemical composition of the delivered vial. Researchers can review validated analytical benchmarks in our research library hub.
Endotoxins—lipopolysaccharide (LPS) complexes originating from the outer membrane of Gram-negative bacteria—pose a significant threat to cell culture assays and animal models. Even highly purified peptides can carry biological endotoxins if water, glassware, or processing equipment lack adequate depyrogenation validation. When introduced into preclinical research, elevated endotoxin levels induce non-specific inflammatory signaling, cytokine cascades, and altered cell viability, invalidating metabolic and tissue repair data.
PX1 Research enforces strict endotoxin safety thresholds across every batch, confirming levels below 0.1 EU/mg via Chromogenic Recombinant Factor C (rFC) assays. Synthesizing peptides in GMP-compliant facilities and validating every batch in USA-based laboratory environments adds necessary overhead, but it ensures that experimental variables remain tightly controlled. Investing in verified low-endotoxin research compounds prevents costly laboratory contamination and inconsistent experimental outcomes.
Proper handling and reconstitution protocols are vital to preserve structural integrity and prevent premature aggregation of CJC-1295 in experimental environments. Lyophilized CJC-1295 appears as a dense white cake or powder. Prior to reconstitution, vials should be allowed to equilibrate to room temperature inside a laminar flow cabinet to minimize condensation.
For general laboratory research, reconstitution is typically performed using sterile Bacteriostatic Water (containing 0.9% benzyl alcohol) or sterile normal saline (0.9% NaCl), depending on assay compatibility. The diluent should be introduced gently against the glass wall of the vial rather than sprayed directly onto the lyophilized powder mass. Swirl the container with light rotational motion until complete dissolution occurs; vigorous shaking or vortexing must be strictly avoided, as mechanical shear forces can induce peptide denaturation or fibril formation.
Lyophilized CJC-1295 demonstrates excellent thermal stability when stored under proper environmental conditions. Unreconstituted vials stored at -20°C maintain structural stability for up to 24 months. For long-term archive storage, maintaining ambient temperatures of -80°C is recommended to prevent trace hydrolysis and peptide degradation.
Once reconstituted into liquid solution, the peptide exhibits increased susceptibility to enzymatic and chemical degradation. Reconstituted CJC-1295 solution should be stored at 2°C to 8°C and evaluated within 14 to 28 days to prevent secondary breakdown. Multiple freeze-thaw cycles must be strictly avoided, as ice crystal formation disrupts the peptide's tertiary structure and causes irreversible loss of bioactivity. Vials should also be shielded from direct ultraviolet light exposure.
The supply chain origin directly correlates with peptide quality, reproducibility, and pricing structure. Unregulated overseas suppliers frequently utilize low-grade synthesis reagents, resulting in residual organic solvents, heavy metals, and uncharacterized diastereomers in final preparations. These impurities distort experimental observations in cell signaling, receptor binding, and tissue regeneration studies.
PX1 Research prioritizes full supply-chain transparency. All compounds are synthesized in state-of-the-art, GMP-compliant facilities and tested in USA-based ISO 17025 laboratories. Orders ship directly from fulfillment centers in California and Arizona, with same-day shipping offered Monday through Friday. Researchers interested in deep-dive chemical properties and synthesis parameters can explore our dedicated article on CJC-1295 mechanism and preclinical data.
What is the typical CJC 1295 price range for research applications?
High-purity CJC-1295 typically costs between $30 and $80 per vial depending on total mass (2 mg or 5 mg), structural modifications (with or without DAC), and the depth of third-party analytical testing provided with the lot.
Why does CJC-1295 DAC cost more than CJC-1295 No DAC?
CJC-1295 DAC contains a complex chemical modification—a maleimide-bearing Drug Affinity Complex added to the Lysine residue—which requires additional synthetic steps, specialized reagents, and additional purification stages during manufacturing.
How can researchers verify the purity of a CJC-1295 order?
Purity is verified by reviewing a lot-specific Certificate of Analysis (COA) generated by an independent ISO 17025 accredited laboratory. The COA must include RP-HPLC trace analysis (showing ≥99% purity) and Mass Spectrometry (MS) confirming expected molecular mass.
What solvent should be used for CJC-1295 laboratory reconstitution?
Standard laboratory reconstitution uses sterile Bacteriostatic Water or sterile 0.9% Normal Saline under aseptic conditions inside a laminar flow hood, depending on downstream assay requirements.
What endotoxin limits are acceptable for CJC-1295 research use?
High-grade research peptides should demonstrate endotoxin levels below 0.1 EU/mg via chromogenic rFC assay to prevent inflammatory interference in cell cultures or animal models.
What is the primary target receptor of CJC-1295 in preclinical studies?
CJC-1295 targets the Growth Hormone-Releasing Hormone (GHRH) receptor on pituitary somatotrophs, driving sustained GH synthesis and subsequent downstream IGF-1 expression.
How should reconstituted CJC-1295 be stored in the laboratory?
Reconstituted solutions must be refrigerated at 2°C to 8°C, protected from light, and utilized within 14–28 days. Repeated freeze-thaw cycles must be avoided to prevent peptide degradation.
Are PX1 Research compounds tested for heavy metals and residual solvents?
Yes. Every lot undergoes rigorous testing, including RP-HPLC, mass spectrometry, heavy metal screening, and endotoxin quantification to ensure pure, unadulterated research compounds.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.